Trials / Unknown
UnknownNCT05164939
Precision Medicine Intervention in Severe Asthma (PRISM) Study
Precision Medicine Intervention in Severe Asthma (PRISM) Study: Molecular Phenotyping of Participants With Severe Asthma to Determine Response to Biologic Therapies and Stability
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The Korea-UK Precision Medicine Intervention in Severe Asthma (PRISM) study aims to identify molecular phenotypes of severe asthma by analyzing multi-omics data including genomics, epigenomics, transcriptomics, proteomics, metagenomics, and metabolomics.
Detailed description
This is a prospective, observational cohort study. The participants are composed of the patients having severe asthma treated with biologic agents or conventional medication. Once enrolled, regular evaluation of clinical characteristics and obtainment of samples for omics analysis is conducted to identify clinically relevance molecular signals in severe asthmatics.
Conditions
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2021-12-21
- Last updated
- 2021-12-21
Locations
2 sites across 2 countries: South Korea, United Kingdom
Source: ClinicalTrials.gov record NCT05164939. Inclusion in this directory is not an endorsement.